Harrow (HROW) Competitors $34.22 -0.21 (-0.61%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends HROW vs. BBIO, GRFS, CRNX, ALKS, AXSM, RARE, BHVN, APLS, PBH, and RNAShould you be buying Harrow stock or one of its competitors? The main competitors of Harrow include BridgeBio Pharma (BBIO), Grifols (GRFS), Crinetics Pharmaceuticals (CRNX), Alkermes (ALKS), Axsome Therapeutics (AXSM), Ultragenyx Pharmaceutical (RARE), Biohaven (BHVN), Apellis Pharmaceuticals (APLS), Prestige Consumer Healthcare (PBH), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical preparations" industry. Harrow vs. BridgeBio Pharma Grifols Crinetics Pharmaceuticals Alkermes Axsome Therapeutics Ultragenyx Pharmaceutical Biohaven Apellis Pharmaceuticals Prestige Consumer Healthcare Avidity Biosciences Harrow (NASDAQ:HROW) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, community ranking, risk, analyst recommendations, media sentiment, earnings and profitability. Do analysts prefer HROW or BBIO? Harrow presently has a consensus price target of $63.00, suggesting a potential upside of 84.10%. BridgeBio Pharma has a consensus price target of $47.69, suggesting a potential upside of 80.04%. Given Harrow's stronger consensus rating and higher probable upside, equities research analysts clearly believe Harrow is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harrow 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00BridgeBio Pharma 0 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.86 Does the media favor HROW or BBIO? In the previous week, BridgeBio Pharma had 6 more articles in the media than Harrow. MarketBeat recorded 9 mentions for BridgeBio Pharma and 3 mentions for Harrow. Harrow's average media sentiment score of 1.13 beat BridgeBio Pharma's score of 0.90 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of HROW or BBIO? 72.8% of Harrow shares are held by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are held by institutional investors. 13.7% of Harrow shares are held by insiders. Comparatively, 24.7% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher valuation and earnings, HROW or BBIO? Harrow has higher earnings, but lower revenue than BridgeBio Pharma. Harrow is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarrow$169.14M7.21-$24.41M-$0.94-36.40BridgeBio Pharma$217.77M22.99-$643.20M-$2.41-10.99 Is HROW or BBIO more profitable? Harrow has a net margin of -19.75% compared to BridgeBio Pharma's net margin of -201.53%. BridgeBio Pharma's return on equity of 0.00% beat Harrow's return on equity.Company Net Margins Return on Equity Return on Assets Harrow-19.75% -45.57% -8.87% BridgeBio Pharma -201.53%N/A -74.34% Which has more volatility and risk, HROW or BBIO? Harrow has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Does the MarketBeat Community favor HROW or BBIO? BridgeBio Pharma received 78 more outperform votes than Harrow when rated by MarketBeat users. Likewise, 71.06% of users gave BridgeBio Pharma an outperform vote while only 58.55% of users gave Harrow an outperform vote. CompanyUnderperformOutperformHarrowOutperform Votes8958.55% Underperform Votes6341.45% BridgeBio PharmaOutperform Votes16771.06% Underperform Votes6828.94% SummaryBridgeBio Pharma beats Harrow on 11 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Harrow News Delivered to You Automatically Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HROW vs. The Competition Export to ExcelMetricHarrowPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.22B$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-36.4010.5990.1317.20Price / Sales7.21196.061,117.09117.04Price / CashN/A57.1643.1037.85Price / Book17.025.094.784.78Net Income-$24.41M$151.83M$120.31M$225.60M7 Day Performance-3.61%-2.14%-1.92%-1.23%1 Month Performance-20.23%-4.56%13.65%0.46%1 Year Performance223.75%8.87%28.34%15.24% Harrow Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HROWHarrow2.389 of 5 stars$34.22-0.6%$63.00+84.1%+221.0%$1.22B$169.14M-36.40182Positive NewsBBIOBridgeBio Pharma4.6961 of 5 stars$27.74+0.9%$47.69+71.9%-31.7%$5.24B$217.77M-11.63400GRFSGrifols3.4529 of 5 stars$7.61+3.8%N/A-28.3%$5.23B$7.01B0.0023,737Gap UpCRNXCrinetics Pharmaceuticals4.0769 of 5 stars$54.15+0.9%$70.82+30.8%+54.2%$5.02B$1.04M-14.39210Positive NewsALKSAlkermes4.6622 of 5 stars$30.45-0.2%$35.42+16.3%+7.8%$4.93B$1.51B15.652,100Positive NewsAXSMAxsome Therapeutics4.769 of 5 stars$90.90+0.9%$125.93+38.5%+25.2%$4.41B$270.60M-13.80589Positive NewsRAREUltragenyx Pharmaceutical4.4414 of 5 stars$46.29+1.1%$87.46+88.9%-2.9%$4.27B$434.25M-7.081,276Analyst ForecastNews CoveragePositive NewsBHVNBiohaven3.7245 of 5 stars$40.92+6.4%$63.00+54.0%-4.6%$4.14B$462.51M-4.11239Analyst ForecastAPLSApellis Pharmaceuticals4.5696 of 5 stars$33.25+0.2%$49.94+50.2%-39.0%$4.14B$396.59M-16.35702Analyst DowngradePositive NewsPBHPrestige Consumer Healthcare3.7935 of 5 stars$82.65+0.4%$85.25+3.1%+27.6%$4.08B$1.11B20.02540Analyst UpgradePositive NewsRNAAvidity Biosciences2.1835 of 5 stars$33.62+3.5%$63.60+89.2%+250.4%$4.01B$10.12M-11.28190Analyst ForecastInsider TradeAnalyst RevisionNews Coverage Related Companies and Tools Related Companies BridgeBio Pharma Alternatives Grifols Alternatives Crinetics Pharmaceuticals Alternatives Alkermes Alternatives Axsome Therapeutics Alternatives Ultragenyx Pharmaceutical Alternatives Biohaven Alternatives Apellis Pharmaceuticals Alternatives Prestige Consumer Healthcare Alternatives Avidity Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HROW) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HROW Stock Alerts